Fierce Pharma
OCTOBER 31, 2024
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | The FDA this week revised its shortage list to note that the.25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S.
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 31, 2024
Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potentia | Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra. In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall Street's expectations and triggered a 16% surge in Madrigal's share price.
pharmaphorum
OCTOBER 31, 2024
Compass Pathways will cut its headcount by 30% as it defers phase 3 readouts for its psychedelic therapy for treatment-resistant depression.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
OCTOBER 31, 2024
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.
pharmaphorum
OCTOBER 31, 2024
The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 31, 2024
Our latest round-up of financings in the biotech sector features Alpha-9 Oncology, Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Therapeutics.
Fierce Pharma
OCTOBER 31, 2024
With U.S. | With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, however, is that while sales from Eylea HD increased by 29% sequentially, this didn't translate to a similar bump in overall U.S. revenue for the Eylea family of eye medications.
PharmaTimes
OCTOBER 31, 2024
The new Dementia Trials Accelerator is set to receive £20m of government funding
Fierce Pharma
OCTOBER 31, 2024
Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push. | Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push. The drugmaker is "exploring opportunities to further improve productivity and efficiency," CEO Chris Boerner said Thursday.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
OCTOBER 31, 2024
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
Fierce Pharma
OCTOBER 31, 2024
Author: Harietta Eleftherochorinou, Vice President, AI Strategy and Operations, IQVIA | We are entering a new era of AI in life sciences, where generative AI, conversational AI and AI agents are transforming day-to-day operations.
pharmaphorum
OCTOBER 31, 2024
Lexeo reveals "promising" early data for gene therapy for APOE4-associated Alzheimer's, but shares in the biotech fall.
Fierce Pharma
OCTOBER 31, 2024
AstraZeneca executives past and present are under investigation in China. GSK is paying $300 million upfront to obtain a T-cell engager to develop for autoimmune diseases. | AstraZeneca executives past and present are under investigation in China. GSK is paying $300 million upfront to obtain a T-cell engager to develop for autoimmune diseases. Takeda has hit a setback with its orexin receptor 2 agonist danavorexton.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
OCTOBER 31, 2024
Septerna's protracted IPO on the Nasdaq has finally reached its conclusion, with the final amount raised by the GPCR-focused biotech above $331m
PharmaVoice
OCTOBER 31, 2024
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
MedCity News
OCTOBER 31, 2024
Novo Holdings led the Series A investment in Kivu Biosciences, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary. The post Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs appeared first on MedCity News.
Healthcare Success
OCTOBER 31, 2024
Whenever we partner with multilocation healthcare providers, we know that some of their locations will need more marketing “nutrition" than others. Still, we often must persuade leadership that all their locations need at least some love—even those with a full census. How can you invest your marketing dollars and energy appropriately across your multilocation portfolio?
Pharmaceutical Technology
OCTOBER 31, 2024
Reeves' budget promised investment for innovation and R&D with a view to "harnessing the full potential of the UK’s science base”.
European Pharmaceutical Review
OCTOBER 31, 2024
Announcement of the UK Government’s 2024 Autumn Budget on 30 October marks the first Labour budget in 14 years. It pledges to benefit key industry sectors across life sciences including R&D, innovation, manufacturing and medicine. Commitment to manufacturing the £520 million life sciences innovative manufacturing fund is very welcome, and will be crucial in helping to capture high-productivity investment” The Association of the British Pharmaceutical Industry (ABPI) backed the proposed
Pharmaceutical Commerce
OCTOBER 31, 2024
Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.
European Pharmaceutical Review
OCTOBER 31, 2024
New Phase III analysis reports that an Itovebi TM (inavolisib)-based combination treatment more than doubled progression-free survival in advanced breast cancer patients. The treatment lowered disease risk worsening or death by 57 percent, according to the analysis from Roche’s Phase III INAVO120 study. This was in comparison to palbociclib and fulvestrant only.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Commerce
OCTOBER 31, 2024
The latest news for pharma industry insiders.
Pharmacy Times
OCTOBER 31, 2024
Incorporating the teach-back method and providing patient handouts expand health knowledge.
PM360
OCTOBER 31, 2024
[Cedar Knolls, 10/29/2024] — A recent study conducted by PURE , the industry’s premier benchmark for evaluating patient support programs (PSPs), has named the best-in-class PSPs across key therapeutic areas. These programs, designed to help patients with access, affordability, and adherence, were evaluated by healthcare professionals (HCPs) based on the ability to address patient needs throughout the treatment journey.
Pharmacy Times
OCTOBER 31, 2024
The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.
PharmExec
OCTOBER 31, 2024
Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.
Pharmacy Times
OCTOBER 31, 2024
Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.
PharmaTech
OCTOBER 31, 2024
The treatment for ATTR in certain adults with polyneuropathy had just been recommended for approval across the European Union and had gained regulatory approval in the United States at the end of 2023.
Pharmaceutical Technology
OCTOBER 31, 2024
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
334 
Let's personalize your content